Class REMS For Botulinum Toxin Products Warns Against Interchangeabilty
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA announced a class-wide REMS for botulinum toxin products that focuses on the dangers on interchangeability of the drugs.
You may also be interested in...
Declaring Victory: How FDA Releases REMS
There is a new category of FDA action letter: a REMS release. Dozens of sponsors of “MedGuide-only” REMS received them after an FDA policy change. But now, FDA is issuing them regularly to sponsors whose communication plans have met their goals – or at least run their course.
Botox For Migraine: How Will The Market Size Up?
The U.S. approval of Allergan Inc.’s Botox (onabotulinumtoxinA) to treat chronic migraines will surely be a boon to the company, but anyone attempting to pin down the market impact of the approval will encounter enough variables to cause a splitting headache.
Allergan Continues To Find New Uses For Botox: Cleared For Chronic Migraine In The UK
30 injections around the head needed to control chronic migraines with Botox.